GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S. Food and Drug Administration (FDA) has cleared ...
The P hase II study for diabetes is a 13-week, randomized, double-blind, placebo-controlled and multi-center study to evaluate the efficacy, safety, and tolerability of ASC30 ...
Switzerland: A randomized trial has found that adding a daily fish oil supplement to psychotherapy did not provide any ...
Insilico Medicine achieved an R&D collaboration with Servier valued at up to US$888 million, focused on discovering and developing innovative oncology ...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ('HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the Phase III ...
Insilico Medicine announced that it has entered into a multi-year research and development (R&D) collaboration with Servier, an ...
To Jagannath, cure means long periods of disease-free survival as defined by minimal residual disease (MRD) criteria, 10 -5 ...
Researchers find that communication between key brain regions shortly after injury may predict long-term functional recovery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback